Resolution No. 2/18-1

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

VACCINES FOR CHILDREN PROGRAM

VACCINES TO PREVENT INFLUENZA

The purpose of this resolution is to add live attenuated influenza vaccine (LAIV) to the VFC program.

VFC resolution 6/17-1 is repealed and replaced by the following:

A. Inactivated Influenza Vaccine (IIV)

Eligible Groups
All children aged 6 months through 18 years.

Recommended Vaccination Schedule
- 6 months through 8 years: 1 or 2 doses, as noted in the current ACIP recommendations
- 9 through 18 years: 1 dose

The table below lists the currently approved inactivated influenza vaccines in the VFC program, including the age indications for each vaccine.

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Presentation</th>
<th>Age Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afluria (Trivalent)</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;= 5 years</td>
</tr>
<tr>
<td>Afluria (Trivalent)</td>
<td>5.0mL multidose vial</td>
<td>&gt;= 5 years</td>
</tr>
<tr>
<td>Afluria (Quadrivalent)</td>
<td>0.25mL pre-filled syringe</td>
<td>&gt;= 6 through 35 months</td>
</tr>
<tr>
<td>Afluria (Quadrivalent)</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;= 36 months</td>
</tr>
<tr>
<td>Afluria (Quadrivalent)</td>
<td>5.0mL multidose vial</td>
<td>&gt;=36 month</td>
</tr>
<tr>
<td>Fluarix (Quadrivalent)</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;= 6 months</td>
</tr>
<tr>
<td>Flucelvax (Quadrivalent)</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;= 4 years</td>
</tr>
<tr>
<td>Flulaval (Quadrivalent)</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;= 6 months</td>
</tr>
<tr>
<td>Flulaval (Quadrivalent)</td>
<td>5.0 mL multidose vial</td>
<td>&gt;= 6 months</td>
</tr>
<tr>
<td>Fluvirin (Trivalent)</td>
<td>0.5 mL pre-filled syringe</td>
<td>&gt;= 4 years</td>
</tr>
<tr>
<td>Fluvirin (Trivalent)</td>
<td>5.0 mL multidose vial</td>
<td>&gt;= 4 years</td>
</tr>
<tr>
<td>Fluzone (Quadrivalent)</td>
<td>0.25mL pre-filled syringe</td>
<td>&gt;= 6 through 35 months</td>
</tr>
<tr>
<td>Fluzone (Quadrivalent)</td>
<td>0.5mL prefilled syringe/vial</td>
<td>&gt;= 6 months</td>
</tr>
<tr>
<td>Fluzone (Quadrivalent)</td>
<td>5.0mL multidose vial</td>
<td>&gt;= 6 months</td>
</tr>
</tbody>
</table>

Note: The use of brand names is not meant to preclude the use of other comparable licensed vaccines.

*Updated 10/9/2018 to include expanded age indications for Afluria Quadrivalent vaccine effective 10/4/2018. **Updated 3/13/2019 to include expanded age indication for Fluzone 0.5mL prefilled syringe/vial effective 1/23/2019.
Recommended Intervals
Minimum Age: 6 months
Minimum interval between dose 1 and dose 2 (where applicable): 4 weeks

Recommended Dosage
Refer to product package insert.

Contraindications and Precautions
Contraindications:
1. History of severe allergic reaction to any component of the vaccine or after previous dose of any influenza vaccine. However, ACIP makes specific recommendations for the use of influenza vaccine in persons with egg allergy (see Influenza Vaccination of Persons with a History of Egg Allergy, in https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm).

Precautions:
1. Moderate or severe acute illness with or without fever
2. GBS within 6 weeks following a previous dose of influenza vaccine

B. Live Attenuated Influenza Vaccine (LAIV)

Eligible Groups
All healthy, non-pregnant children and adolescents (those who do not have an underlying medical condition that predisposes them to influenza complications) aged 2 through 18 years.

Recommended Vaccination Schedule
- 2 years through 8 years: 1 or 2 doses, as noted in the current ACIP recommendations
- 9 through 18 years: 1 dose

Recommended Intervals
Minimum Age: 2 years
Minimum interval between dose 1 and dose 2 (where applicable): 4 weeks

Recommended Dosage
Refer to product package insert.

Contraindications and Precautions
Contraindications and precautions can be found at: https://www.cdc.gov/mmwr/volumes/66/rr/rr6602a1.htm

[If an ACIP recommendation regarding influenza vaccination is published within 6 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the URL.]
Adopted and Effective: February 21, 2018

This document can be found on the CDC website at: